Pear Therapeutics president and CEO Corey McCann (Pear)

Pear Ther­a­peu­tics nabs $80M Se­ries D to com­mer­cial­ize three dig­i­tal ther­a­peu­tics

As the pan­dem­ic rages on, vir­tu­al care op­tions have in­vestors champ­ing at the bit. Boston-based Pear Ther­a­peu­tics is the lat­est to ben­e­fit, reel­ing in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.